September 7, 2021
“Wall Street’s favorites among the S&P 500 Analysts who work for brokerage firms tend to shy away from negative ratings. Among the S&P 500, there are no companies with majority “sell” or equivalent ratings. But the analysts still have clear… Continue Reading…
September 3, 2021
“Almost half of U.S. workers, 48%, say they don’t earn enough income to save for retirement, according to a new survey from the Transamerica Center for Retirement Studies. The finding is pretty consistent across generational groups. On the high end, 55% of… Continue Reading…
July 13, 2021
“A Bonanza Of Profit Is Coming Analysts see 1,000% or more profit growth from these S&P 500 companies in the second quarter Company Ticker Q2 EPS % Ch. Primary Sector Composite Rating % stock YTD ch. Zimmer Biomet (ZBH) 3,620.0%… Continue Reading…
July 13, 2021
“TaskUs (TASK)… This newly public stock has attracted no fewer than 9 analyst reviews in its short time on the public markets. Those reviews break down 8 to 1 in favor of the Buy over Hold, giving TASK a Strong Buy… Continue Reading…
July 13, 2021
“Baidu (NASDAQ: BIDU)… …Overall, 17 Wall Street analysts have weighed in on Baidu shares in the past three months, giving the stock 14 Buys and 3 Holds for a Strong Buy consensus rating. The average Baidu price target of $304.40 implies approximately 67.8% upside… Continue Reading…
July 1, 2021
“After a jaw-dropping rally this spring, lumber prices have come back down to earth as supply increased, speculative trading action cooled and homebuilding demand eased. Lumber futures tanked more than 40% in June alone, suffering their worst month on record dating back… Continue Reading…
June 29, 2021
“Day One Biopharmaceuticals (DAWN)… Overall, there is broad agreement on Wall Street with Rama’s view, as indicated by the unanimous Strong Buy consensus rating, supported by 4 recent positive reviews. Shares in DAWN are selling for $20.11 and their $37.33 average… Continue Reading…
June 22, 2021
“Paymentus Holdings (PAY)… Overall, PAY has received 8 recent analyst reviews, breaking down to 6 Buys versus 2 Holds and making the analyst consensus rating a Strong Buy. The stock has current trading price of $32.35 and an average price… Continue Reading…
June 14, 2021
“Shares of iTeos Therapeutics Inc. ITOS, 30.79% soared 58.5% in premarket trading on Monday after the company announced a deal with GlaxoSmithKline GSK, +0.39% to develop and commercialize an experimental cancer therapy. GSK will make a $625 million upfront payment to iTeos, with an additional $1.4… Continue Reading…
Recent Comments